BRD2 and pancreatic adenocarcinoma: Additionally, the Phase II trial SWOG1505 explored the potential benefit of either mFOLFIRINOX or gemcitabine/nab-paclitaxel as NAT in resectable pancreatic adenocarcinoma [39].